Skip to content

Study · Animal study (in vivo) · rat · 2019

6 results

Exacerbation of blood-brain barrier breakdown, edema formation, nitric oxide synthase upregulation and brain pathology after heat stroke in diabetic and hypertensive rats. Potential neuroprotection with cerebrolysin treatment.

Muresanu DF, Sharma A, Patnaik R, Menon PK, Mössler H, Sharma HS

International review of neurobiology18 Jul 2019Cited by 19 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic-hypertensive rats exposed to heat stress, high-dose Cerebrolysin induced significant neuroprotection.

    In plain wordsIn rats with diabetes and hypertension, high-dose Cerebrolysin protected the brain during heat stress.

    Outcome
    IncreaseNeuroprotection
    Study

    ratn: not reported in source

    diabetic-hypertensive heat-stress rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10-mL/kg · i.v.As given in this study (rat).

    Source sentences

    Summary
    Cerebrolysin in high doses (10-mL/kg, i.v. instead of 5-mL/kg) induced significant neuroprotection and downregulation of nNOS and iNOS in DBHY animals whereas normal animals need only 5-mL/kg doses for this purpose.
    1 context sentence
    Summary · context
    This hypothesis is examined in a rat model.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In diabetic-hypertensive rats, high-dose Cerebrolysin downregulated nNOS.

    In plain wordsIn rats with diabetes and hypertension, high-dose Cerebrolysin reduced nNOS expression.

    Outcome
    DecreasenNOS expression
    Study

    ratn: not reported in source

    diabetic-hypertensive heat-stress rats
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10-mL/kg · i.v.As given in this study (rat).

    Source sentences

    Summary
    Cerebrolysin in high doses (10-mL/kg, i.v. instead of 5-mL/kg) induced significant neuroprotection and downregulation of nNOS and iNOS in DBHY animals whereas normal animals need only 5-mL/kg doses for this purpose.
    1 context sentence
    Summary · context
    This hypothesis is examined in a rat model.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In diabetic-hypertensive rats, high-dose Cerebrolysin downregulated iNOS.

    In plain wordsIn rats with diabetes and hypertension, high-dose Cerebrolysin reduced iNOS expression.

    Outcome
    DecreaseiNOS expression
    Study

    ratn: not reported in source

    diabetic-hypertensive heat-stress rats
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10-mL/kg · i.v.As given in this study (rat).

    Source sentences

    Summary
    Cerebrolysin in high doses (10-mL/kg, i.v. instead of 5-mL/kg) induced significant neuroprotection and downregulation of nNOS and iNOS in DBHY animals whereas normal animals need only 5-mL/kg doses for this purpose.
    1 context sentence
    Summary · context
    This hypothesis is examined in a rat model.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats exposed to heat stress, Cerebrolysin induced neuroprotection at 5-mL/kg.

    In plain wordsIn normal rats exposed to heat stress, Cerebrolysin protected the brain at 5-mL/kg.

    Outcome
    IncreaseNeuroprotection in normal rats
    Study

    ratn: not reported in source

    normal rats exposed to heat stress
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    5-mL/kg · i.v.As given in this study (rat).

    Source sentences

    Summary
    Cerebrolysin in high doses (10-mL/kg, i.v. instead of 5-mL/kg) induced significant neuroprotection and downregulation of nNOS and iNOS in DBHY animals whereas normal animals need only 5-mL/kg doses for this purpose.
    1 context sentence
    Summary · context
    This hypothesis is examined in a rat model.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In normal rats exposed to heat stress, Cerebrolysin downregulated nNOS at 5-mL/kg.

    In plain wordsIn normal rats exposed to heat stress, Cerebrolysin reduced nNOS expression at 5-mL/kg.

    Outcome
    DecreasenNOS expression in normal rats
    Study

    ratn: not reported in source

    normal rats exposed to heat stress
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    5-mL/kg · i.v.As given in this study (rat).

    Source sentences

    Summary
    Cerebrolysin in high doses (10-mL/kg, i.v. instead of 5-mL/kg) induced significant neuroprotection and downregulation of nNOS and iNOS in DBHY animals whereas normal animals need only 5-mL/kg doses for this purpose.
    1 context sentence
    Summary · context
    This hypothesis is examined in a rat model.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In normal rats exposed to heat stress, Cerebrolysin downregulated iNOS at 5-mL/kg.

    In plain wordsIn normal rats exposed to heat stress, Cerebrolysin reduced iNOS expression at 5-mL/kg.

    Outcome
    DecreaseiNOS expression in normal rats
    Study

    ratn: not reported in source

    normal rats exposed to heat stress
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    5-mL/kg · i.v.As given in this study (rat).

    Source sentences

    Summary
    Cerebrolysin in high doses (10-mL/kg, i.v. instead of 5-mL/kg) induced significant neuroprotection and downregulation of nNOS and iNOS in DBHY animals whereas normal animals need only 5-mL/kg doses for this purpose.
    1 context sentence
    Summary · context
    This hypothesis is examined in a rat model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.